

(PF1221) OVERCOMING LACTATE-MEDIATED T CELL SUPPRESSION VIA PTPN1 INHIBITION: A NOVEL STRATEGY TO ENHANCE CAR-T CELL EFFICACY IN MULTIPLE MYELOMA

Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Biology & translational research

Siyin Chen¹, Xi Zhang¹, Aishun Jin^{*2}

¹Xinqiao Hospital ARMY Medical University, Hematology department, Chongqing, China; ²Chongqing medical university, Chongqing, China;

Background

Background: In multiple myeloma, tumor cell metabolism and hypoxia lead to lactate accumulation and an acidic microenvironment. Lactate suppresses T cell anti-tumor capabilities, including those of CAR-T cells. The limited clinical efficacy of CAR-T in multiple myeloma pressing for the need to uncover mechanisms that sustain T cell activity under lactate conditions. Identifying mechanisms that sustain T cell function under lactate conditions is therefore crucial for improving CAR-T cell efficacy in hematological cancers. This study identified genetic regulators that preserve T cell function under

Aims

Aims: This study aims to identify key regulators that maintain T cell function under the immunosuppressive conditions of the multiple myeloma tumor microenvironment, specifically focusing on overcoming lactate-induced suppression. We will investigate the role of PTPN1 in T cell activation and effector function in the presence of lactate and evaluate its potential as a therapeutic target to enhance CAR-T cell efficacy.

Methods

Methods: We performed a genome-wide CRISPR knockout (KO) screen in human Jurkat T cells to identify genes critical for maintaining CD25 expression under lactate stress. Cells were stimulated with anti-CD3 and anti-CD28 antibodies in the presence of 15 mM lactate, followed by sorting of CD25⁺ and CD25⁻ populations and next-generation sequencing (NGS). Candidate genes were validated through in vitro assays in primary T cells and, crucially, in ex vivo expanded T cells representative of those used in adoptive cell therapy.

Results

Results: The CRISPR screen identified Protein Tyrosine Phosphatase Non-receptor type 1 (PTPN1) as a crucial regulator of T cell activation in the presence of lactate. Mechanistically, lactate suppressed CD8⁺ T cell activation and cytotoxic function by reducing oxidative modification of PTPN1 at cysteine 215 (Cys215). This redox shift impaired TCR/IL-2/STAT5 signaling and effector cytokine production. Crucially, both genetic ablation of *PTPN1* and pharmacological inhibition using AC484 significantly rescued T cell signaling and restored the anti-tumor function of ex vivo expanded CD8⁺ T cells, including their cytotoxic capacity, under lactate-rich conditions. These findings demonstrate that PTPN1 plays a critical role in mediating lactate-induced suppression of T cell effector function relevant to adoptive cell therapy.

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the "Author Information" page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

Summary/Conclusion

Conclusions: Lactate suppresses T cell function, including that of CAR-T cells, by shifting the redox state of PTPN1 towards a less oxidized conformation, thereby impairing T cell signaling. Targeting PTPN1 restores T cell activation and effector functions under lactate stress, highlighting PTPN1 as a potential therapeutic target to enhance CAR-T cell persistence and efficacy in the acidic TME of hematological malignancies. These findings offer a novel strategy to overcome metabolic barriers and improve the clinical success of CAR-T cell immunotherapy.

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the “Author Information” page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.